High Sam68 expression predicts poor prognosis in non-small cell lung cancer

Clinical and Translational Oncology

Volumn 16, Issue 10, 2014, Pages 886-891

  Zhang, Z ^a   Xu, Y ^a   Sun, N ^a   Zhang, M ^a   Xie, J ^a   Jiang, Z ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Non small cell lung cancer; Prognosis; Sam68

Indexed keywords

BIOLOGICAL MARKER; NUCLEAR PROTEIN; NUCLEAR PROTEIN SAM 68; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; KHDRBS1 PROTEIN, HUMAN; MESSENGER RNA; RNA BINDING PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; COHORT ANALYSIS; GENETICS; LUNG TUMOR; METABOLISM; MORTALITY; PROGNOSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84929940814     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1160-3     Document Type: Article

References (25)

1. Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S, Agrawal A. Lung cancer biomarkers: state of the art. J Carcinog. 2013;12:3.
2. Tsim S, O’Dowd CA, Milroy R, Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med. 2010;104:1767–74.
3. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 2009;5:745–55.
4. Stuschke M, Pöttgen C. Chemotherapy: effectiveness of adjuvant chemotherapy for resected NSCLC. Nat Rev Clin Oncol. 2010;7:613–4.
5. Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD. Multiple endpoint analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer. 2008;122:1810–9.
6. Filipits M, Pirker R. Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer. 2011;74:355–63.
7. Lukong KE, Richard S. Sam68, the KH domain-containing superSTAR. Biochim Biophys Acta. 2003;13:73–86.
8. Taylor SJ, Shalloway D. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature. 1994;368:867–71.
9. Fumagalli S, Totty NF, Hsuan JJ, Courtneidge SA. A target for Src in mitosis. Nature. 1994;13:871–4.
10. Bielli P, Busa R, Paronetto MP, Sette C. The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer. 2011;13: R91–102.
11. Babic I, Cherry E, Fujita DJ. SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis. Oncogene. 2006;13:4955–64.
12. Busa R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF, et al. The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene. 2007;13:4372–82.
13. Song L, Wang L, Li Y, Xiong H, Wu J, Li J, et al. Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J Pathol. 2010;13:227–37.
14. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–71.
15. Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam 68. Nature. 2002;13:691–5.
16. Paronetto MP, Cappellari M, Busa R, Pedrotti S, Vitali R, Comstock C, et al. Alternative splicing of the cyclin D1 protooncogene is regulated by the RNAbinding protein Sam 68. Cancer Res. 2011;70:229–39.
17. Valacca C, Bonomi S, Buratti E, Pedrotti S, Baralle FE, Sette C, et al. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol. 2010;191:87–99.
18. Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, et al. Regulation of gene expression by the RNA-binding protein Sam68 in cancer. Biochem Soc Trans. 2008;36:505–7.
19. Liu K, Li L, Nisson PE, Gruber C, Jessee J, Cohen SN. Neoplastic transformation and tumorigenesis associated with sam68 protein deficiency in cultured murine fibroblasts. J Biol Chem. 2000;275:40195–201.
20. Taylor SJ, Resnick RJ, Shalloway D. Sam68 exerts separable effects on cell cycle progression and apoptosis. BMC Cell Biol. 2004;5:5.
21. Richard S, Vogel G, Huot ME, Guo T, Muller WJ, Lukong KE. Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis. Oncogene. 2008;27:548–56.
22. Li Z, Yu CP, Zhong Y, Liu TJ, Huang QD, Zhao XH, et al. Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Ann Oncol. 2012;23:638–46.
23. Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z, et al. Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Cancer Epidemiol Biomark Prev. 2009;18:2685–93.
24. Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol. 2007;13:929–39.
25. Chawla G, Lin CH, Han A, Shiue L, Ares M Jr., Black DL. Sam68 regulates a set of alternatively spliced exons during neurogenesis. Mol Cell Biol. 2009;13:201–13.